CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Nivolumab 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03172624
NCT03172624Phase 2Completed
CompareCT.gov

A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers

Memorial Sloan Kettering Cancer Center·interventional·Posted Jun 1, 2017·Updated Dec 18, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Salivary Gland Cancer. Completed, enrolled 64 participants across 8 sites.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSalivary Gland Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 1, 2017
Enrollment StartMay 26, 2017
Primary CompletionDec 18, 2024
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 9.1 years ago

Interventions

Nivolumabdrug

nivolumab 3 mg/kg every 2 weeks

Ipilimumabdrug

ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)